Oncology Venture Updates Regarding Investor Presentations in Connection with the Rights Issue of New Shares

Investor news

Hørsholm, October 24th, 2019 – Oncology Venture A/S (“Oncology Venture”) today provided an update regarding when its executive management is scheduled to make investor presentations in connection with the rights issue offering in Q4 2019. Please, see below for more details.

Investor meetings

Date and time Organiser Place Registration
October 25th


Direkt Studios


Online: https://www.youtube.com/watch?v=qlMJraIRfBo&feature=youtu.be   No registration needed
October 29th 
17.45 – 20.00



Laika Consulting


GT30, Turbin,Grev Turegatan 30, Stockholm, Sweden


Please register here to attend:
October 30th 17.45 – 20.00


Laika Consulting Elite Park Aveneu Hotel, Kungsportsavenyen 36, Gothenburg, Sweden


Please register here to attend:
October 31th 
17.45 – 20.00
Laika Consulting High Court Meetings, Malmöhusvägen 1, Malmö, Sweden


Please register here to attend:
November 1st
15.45 – 18.00
Danish Shareholders Association Comwell Hotel, Kongevejen 495A, 2840 Holte, Denmark


Please register here to attend:
November 5th 
18.00 – 20.0
Laika Consulting


GT 30, Grev Turegatan 30, Stockholm,


Please register here to attend:
November 6th 
16.00 – 17.00





Online: https://www.proinvestor.com/ir/q-and-a/dk


No registration needed


November 7th 
19.00 – 20.00


Oncology Venture Online
Please register here to attend:

Prospectus and additional information are available on www.oncologyventure.com

For further information, please contact:


Henrik Moltke, CFO
E-mail: [email protected]
Telephone +45 53 63 96 37


About Oncology Venture A/S
Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, DRP®. The company has a mature portfolio of seven drug candidates, including compounds in the pre-registration stage.
The current product portfolio includes: 2X-121 a PARP inhibitor in an ongoing Phase 2 for breast  and ovarian cancer; dovitinib, which will enter Phase 2 trials for indications dependent on further Dovitinib-DRP retrospective/prospective analysis of studies completed by Novartis: Ixabepilone for the treatment of breast cancer. LiPlaCis®, a liposomal formulation of cisplatin in an ongoing Phase 2 trial for breast and prostate cancer 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; irofulven, a Phase 2 is ongoing for prostate cancer; and APO010, an immuno-oncology product in Phase 1/2 for multiple myeloma.

About the Drug Response Predictor – DRP® Companion Diagnostic
Oncology Venture uses its multi gene DRP® to select those patients who by the genetic signature of their cancer are found to have a high likelihood of responding to the drug. By screening patients before treatment the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology. DRP® is based on messenger RNA from the patient’s biopsies.
DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 29 out of 37 clinical studies that were examined.
The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs in the US.

Follow us on social media:
Facebook: https://www.facebook.com/oncologyventure/
LinkedIn: https://www.linkedin.com/company/oncology-venture/
Twitter: https://twitter.com/OncologyVenture

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OV’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OV’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OV undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
will test and develop dovitinib. Oncology Venture A/S has an ownership of 98% in Oncology Venture US and 55% of dovitinib with an opportunity to acquire further 30%. 

Learn more at oncologyventure.com.


Sign up for press releases and receive relevant information about Allarity Therapeutics A/S